Beta Bionics Inc Dossier - Source-backed chat

Beta Bionics Inc

BBNXNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)2.29

Intrinsic Value $18.99median of 2 methodsbased on filings through 30 Jun 2026

Market Price $18.98Price as of 30 Sep 2026

Near fair valueIntrinsic value is 0% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $1B

Enterprise Value $979.6M

Shares Outstanding 48M diluted

Next Earnings Date15 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Beta Bionics, Inc. (NASDAQ:BBNX) has demonstrated impressive top-line growth, with FY 2025 revenue rising 54% to $100.3 million, driven by the commercial expansion of its flagship iLet Bionic Pancreas. The company is successfully shifting its reimbursement mix toward the high-margin Pharmacy Benefit (PBP) channel, which is projected to reach 37% to 39% of new patient starts in 2026. However, Beta Bionics faces significant near-term headwinds, including a sequential decline in new patient starts in Q1 2026, persistent operating losses ($71.7 million in FY 2025), and regulatory scrutiny following a January 2026 FDA Warning Letter regarding its quality systems and unreported adverse events. While its pipeline (Mint patch pump and bihormonal system) offers long-term promise, the company's path to profitability remains highly uncertain, justifying a Hold rating.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets10 analysts · as of 18 Aug 2026

Low · most bearish analyst$13.00

Mean target$19.80

High · most bullish analyst$32.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case reflects prolonged regulatory complications from the FDA Warning Letter, potentially leading to import bans, product recalls, or delayed approvals for the Mint patch pump. Sequential declines in new patient starts persist due to intense competition from established players like Insulet (Omnipod 5) and Tandem Diabetes Care (Mobi). High cash burn depletes the company's $239.5 million liquidity cushion faster than anticipated, forcing a dilutive capital raise.

Base CaseCentral scenario

The base case assumes Beta Bionics successfully executes its commercial strategy, achieving its raised FY 2026 revenue guidance of $131 million to $136 million. Gross margins are expected to expand to the 57.5% to 59.5% range as the higher-margin PBP channel mix scales. The company is expected to resolve the FDA Warning Letter issues without material disruptions to manufacturing or distribution, though remediation costs will continue to weigh on operating margins. The Mint patch pump remains on track for a projected 2027 launch.

Bull CaseUpside scenario

Rapid commercial adoption of the iLet Bionic Pancreas, driven by its unique 'no carb counting' algorithm, is accelerating revenue growth (up 57% YoY in Q1 2026). Strong expansion into the high-margin Pharmacy Benefit Plan (PBP) channel (up 181% YoY in Q1 2026) is driving gross margin expansion to 59.5%. Furthermore, a robust pipeline featuring the 'Mint' patch pump and a bihormonal (insulin + glucagon) system provides a clear path to long-term market leadership in type 1 diabetes care.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong top-line growth with FY 2025 revenue up 54% YoY to $100.3 million.
Favorable shift to the Pharmacy Benefit (PBP) channel, driving gross margin expansion toward 59.5%.
Robust liquidity position with $239.5 million in cash and investments as of Q1 2026.
Differentiated pipeline including the Mint patch pump prototype and a bihormonal bionic pancreas.

Key Investment Risks

Regulatory risk highlighted by the January 2026 FDA Warning Letter regarding quality systems and unreported adverse events.
Intense competition from well-capitalized incumbents like Insulet, Tandem Diabetes Care, and Medtronic.
Persistent operating losses ($71.7 million in FY 2025) and high commercialization expenses.
Sequential volatility in new patient starts, which declined 10% to 20% in Q1 2026.

Thesis Invalidation Triggers

Escalation of FDA regulatory actions (e.g., consent decree, product recalls, or import bans).
A material delay in the clinical development or regulatory submission of the Mint patch pump.
Quarterly revenue growth falling below 20% YoY, indicating a loss of market share to competitors.
Cash burn accelerating to over $30 million per quarter, shortening the runway.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.